Statistics in clinical vaccine trials

Statistics in Clinical Vaccine Trials

Volumn , Issue , 2011, Pages 1-153

  Nauta, Jozef ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889795603     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-14691-6     Document Type: Book

References (73)

1. Vesikari T., Karvonen A., Korhonen T., Espo M., Lebacq E., Forster J., Zepp F., Delem A., De Vos B. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine, 22, 2836-2842, 2004
2. Harro CD., Pang Y. Y. S., Roden R. B. S., Hildesheim A., Wang Z., Reynolds M. J., Mast T. C., Robinson R., Murphy B. R., Karron R. A., Dillner J., Schiller J. T., Lowy D. R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. Journal of the National Cancer Institute, 93, 284-292, 2001
3. Feiring B., Fuglesang J., Oster P., Naess L. M., Helland O. S., Tilman S., Rosenqvist E., Bergsaker M. A. R., Nøkleby H., Aaberge I. S. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clinical and Vaccine Immunology, 13, 790-796, 2006
4. Newcombe R. G. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Statistics in Medicine, 17, 857-872, 1998
5. Borkowf C. B. Constructing binomial confidence intervals with near nominal coverage by adding a single imaginary failure or success. Statistics in Medicine, 25, 3679-3695, 2006
6. Lancaster H. O. Statistical control of counting experiments. Biometrika, 39, 419-422, 1952
7. Lancaster H. O. Significance tests in discrete distributions. Journal of the American Statistical Association, 56, 223-234, 1961
8. Miettinen O., Nurminen M. Comparative analysis of two rates. Statistics in Medicine, 4, 213-226, 1985
9. Chick S. E., Barth-Jones D. C., Koopman J. S. Bias reduction for risk ratio and vaccine effect estimators. Statistics in Medicine, 20, 1609-1624, 2001
10. Suissa S., Shuster JJ. Exact unconditional sample sizes for the 2×2 binomial trial. Journal of the Royal Statistical Society, Series A-Statistics in Society, 148, 317-327, 1985
11. Lydersen S., Fagerland M. W., Laake P. Tutorial in biostatistics: Recommended tests for association in 2×2 tables. Statistics in Medicine, 28, 1159-1175, 2009
12. Chan I. S. F. Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. Statistics in Medicine, 17, 1403-1413, 1998
13. Berger R. L. Multiparameter hypothesis testing and acceptance sampling. Technometrics, 24, 295-300, 1982
14. Laska N. S., Tang D., Meisner MJ. Testing hypothesis about an identified treatment when there are multiple endpoints. Journal of the American Statistical Association, 87, 825-831, 1992
15. Chuang-Stein C, Stryszak P., Dmitrienko A., Offen W. Challenge of multiple co-primary endpoints: A new approach. Statistics in Medicine, 26, 1181-1192, 2007
16. Senn S., Bretz F. Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics, 6, 161-170, 2007
17. Reed G. F, Meade B. D., Steinhoff M. C. The reverse cumulative distribution plot: A graphic method for exploratory analysis of antibody data. Pediatrics, 96, 600-603, 1995
18. Nauta JJ. P, Beyer W. E. P, Osterhaus A. D. M. E. On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals, 37, 216-221, 2009
19. Lachenbruch P. A., Rida W., Kou J. Lot consistency as an equivalence problem. Journal of Biopharmaceutical Statistics, 14, 275-290, 2004
20. Julious S. A. Sample Sizes for Clinical Trials. Chapman and Hall/CRC, 2009
21. Fleiss J. L., Levin B., Paik M. C. Statistical Methods for Rates and Proportions, Third Edition. Wiley-InterScience, Hoboken, New Jersey, 2003
22. Hirji K. F., Tang M. L., Vollset S. E., Elashoff R. M. Efficient power computation for exact and mid-P tests for the common odds ratio in several 2×2 tables. Statistics in Medicine, 13, 1539-1549, 1994
23. Ting Lee M. L., Whitmore G. A. Statistical inference for serial dilution assay data. Biometrics, 55, 1215-1220, 1999
24. Nauta J. J. P., De Bruijn I. A. On the bias in HI titers and how to reduce it. Vaccine, 24, 6645-6646, 2006
25. Lyng J., Weis Bentzon M. International standards for anti-poliovirus sera types 1, 2 and 3. Bulletin of the World Health Organization, 29, 711-720, 1963
26. Nauta J. J. P. Eliminating bias in the estimation of the geometric mean of HI titers. Biologicals, 34, 183-186, 2006
27. Cox D. R., Oakes D. Analysis of Survival data. Chapman and Hall, London, 1984
28. Wang W. W. B., Mehrotra D. V., Chan I. S. F., Heyse J. F. Statistical considerations for non Infe-riority/equivalence trials in vaccine development. Journal of Biopharmaceutical Statistics, 16, 429-441, 2006
29. Schuirmann D. J. A comparison of the two one-sided tests procedure and the power approach for assessing equivalence of average bioavailability. Journal of Pharmacokinetics and Biophar-maceutics, 15, 657-680, 1987
30. United States Food and Drug Administration. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines, May 2007
31. United States Food and Drug Administration. Guidance for industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines., May 2007
32. Joines R. W., Blatter M., Abraham B., Xie F., De Clercq N., Baine Y., Reisinger K. S., Kuhnen A., Parenti D. L. Prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine, Twinrix. with corresponding monovalent vaccines, Havrix and Engerix-B. in adults. Vaccine, 19, 4710-4719, 2001
33. Nauta J. Statistical analysis of influenza vaccine lot consistency studies. Journal of Biophar-maceutical Statistics, 16, 443-452, 2006
34. ICH E9 Expert Working Group. Statistical Principles for Clinical Trials: ICH Harmonised Tripartite Guideline., September 1998
35. Wiens B. L., Iglewicz B. On testing equivalence of three populations. Journal of Biopharma-ceutical Statistics, 9, 465-483, 1999
36. Kong L., Kohberger R. C., Koch G. G. Type I error and power in noninferiority/equivalence trials with correlated multiple endpoints: An example from vaccine development trials. Journal of Biopharmaceutical Statistics, 14, 893-907, 2004
37. Kong L., Kohberger R. C., Koch G. G. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints. Journal of Biopharmaceutical Statistics, 16, 555-572, 2006
38. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, CPMP. Points to consider on switching between superiority and noninferiority. London, 27 July 2000
39. Dunnett C. W., Gent M. An alternative to the use of two-sided tests in clinical trials. Statistics in Medicine, 15, 1729-1738, 1976
40. Morikawa T., Yoshida M. A useful testing strategy in phase III trials: Combined test of superiority and test of equivalence. Journal of Biopharmaceutical Statistics, 5, 297-306, 1995
41. Ng T.-H. Simultaneous testing of noninferiority and superiority increases the false discovery rate. Journal of Biopharmaceutical Statistics, 17, 259-264, 2007
42. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., Leroux-Roels G. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine, 26, 6614-6619, 2008
43. Ganju J., Izu A., Anemona A. Sample size for equivalence trials: A case study from a vaccine lot consistency study. Statistics in Medicine, 27, 3743-3754, 2008
44. Kohberger R. C. Comments on Sample size for equivalence trials: A case study from a vaccine lot consistency trial by J. Ganju, A. Izu and A. Anemona. Statistics in Medicine, 28, 177-178, 2009
45. Ganju J., Izu A., Anemona A. Authors' Reply. Statistics in Medicine, 28, 178-179, 2009
46. Halloran M. E., Longini I. M., Struchiner C. J. Design and interpretation of vaccine field studies. Epidemiological Reviews, 21, 73-88, 1999
47. Halloran M. E. Overview of vaccine field studies: Types of effects and designs. Journal of Biopharmaceutical Statistics, 16, 415-427, 2006
48. Halloran M. E., Longini, Jr. I. M., Struchiner C. J. Design and Analysis of Vaccine Studies. Springer, New York, 2009
49. Orenstein W. A., Bernier R. H., Hinman A. R. Assessing vaccine efficacy in the field - Further observations. Epidemiological Review, 10, 212-241, 1988
50. Blennow M., Olin P., Granström M., Bernier R. H. Protective efficacy of a whole cell pertussis vaccine. British Medical Journal, 296, 1570-1572, 1988
51. Urdaneta M., Prata A., Struchiner C. J., Tosta C. E, Tauil P., Boulos M. Evaluation of SPf66 malaria vaccine efficacy in Brazil. American Journal of Tropical Medicine and Hygiene, 58, 378-385, 1988
52. Moorthy V., Reed Z., Smith P. G. Measurement of malaria vaccine efficacy in phase III trials: Report of a WHO consultation. Vaccine, 25, 5115-5123, 2007
53. Jahn-Eimermacher A., Du Prel J. B., Schmitt H. J. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: A methodological overview of statistical practice in randomized controlled clinical trials. Vaccine, 25, 6237-6244, 2007
54. McCullagh P., Nelder J. A. Generalized Linear Models, Second Edition. Chapman and Hall, London, 1989
55. Andersen P. K., Gill R. D. Cox regression model for counting processes: A large sample study. Annals of Statistics, 10, 1100-1120, 1982
56. Forrest B. D., Pride M. W., Dunning A. J., Capeding M. R., Chotpitayasunondh T., Tam J. S., Rap-paport R., Eldridge J. H., Gruber W. C. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clinical and Vaccine Immunology, 15, 1042-1053, 2008
57. Siber G. R. Methods for estimating serological correlates of protection. Developments in Biological Standardization, 89, 283-296, 1997
58. Hobson B., Curry R. L., Beare A. S., Ward-Gardner A. he role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene, 70, 767-777, 1972
59. Dunning A. J. A model for immunological correlates of protection. Statistics in Medicine, 25, 1485-1497, 2006
60. White C. J., Kuter B. J., Ngai A., Hildebrand C. S., Isganitis K. L., Patterson C. M., Capra A., Miller W. J., Krah D. L., Provost P. J., Ellis R. W., Calandra G. B. Modified cases of chicken-pox after varicella vaccination: correlation of protection with antibody response. Pediatric Infectious Disease Journal, 11, 19-23, 1992
61. Jdar L., Butler J., Carlone G., Dagan R., Goldblatt D., Kyhty H., Klugman K., Plikaytis B., Siber G., Kohberger R., Chang I., Cherian T. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine, 21, 3265-3272, 2003
62. Ellenberg S. S. Safety considerations for new vaccine development. Pharmacoepidemiology and Drug Safety, 10, 411-415, 2001
63. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R. T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. The New England Journal of Medicine, 350, 896-903, 2004
64. Whitaker H. J., Farrington C. P., Spiessen B., Musonda P. Tutorial in biostatistics: The self-controlled case series method. Statistics in Medicine, 25, 1768-1798, 2006
65. Dmitrienko A., Tamhane A. C., Bretz F. (editors) Multiple Testing Problems in Pharmaceutical Statistics. Chapman and Hall/CRC, New York, 2010
66. Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 1995, 57, 289-300, 1995
67. Mehrotra D. V., Heyse J. F. Use of the false discovery rate for evaluating clinical safety data. Statistical Methods in Medical Research, 13, 227-238, 2004
68. Berry S. M., Berry D. A. Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixture model. Biometrics, 60, 418-426, 2004
69. Singh M., ed. Vaccine Adjuvants and Delivery Systems. Wiley, Hobokon, New Jersey, 2007
70. United States Food and Drug Administration. Guidance for Industry: Toxicity Grading Scale for Healthy Adults and Adolescent Volunteers enrolled in Preventive Vaccine Clinical Trials., September 2007
71. De Bruijn I. A., Nauta J., Gerez L., Palache A. M. The virosomal influenza vaccine Invivac: Immunogenicity and tolerability compared to an adjuvanted influenza vaccine, Fluad. in elderly subjects. Vaccine, 24, 6629-6631, 2006
72. Lehmann E. H. J. M. Nonparametrics: Methods Based on Ranks. Springer Science+Bussiness Media, LLC, New York, USA, 2006
73. Diggle L., Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. British Medical Journal, 321, 931-933, 2000